UCB (ENXTBR:UCB) - Cotización, noticias y análisis

Resumen de acción UCB

UCB SA, empresa biofarmacéutica, desarrolla productos y soluciones para personas con enfermedades neurológicas e inmunológicas en todo el mundo. Saber más

Análisis fundamental de UCB
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	4/6
Rendimiento pasado	1/6
Salud financiera	4/6
Dividendos	0/6

Recompensas

Cotiza un 66.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 35.94%

Análisis de riesgos

Los márgenes de beneficio (4.4%) son inferiores a los del año pasado (6.5%)

Competidores de UCB SA

Financière de Tubize

ENXTBR:TUB

€6.1b

Jiangsu Hengrui Medicine

SHSE:600276

CN¥306.9b

Takeda Pharmaceutical

TSE:4502

JP¥6.5t

Otsuka Holdings

TSE:4578

JP¥4.8t

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de UCB
Precios históricos de las acciones
Precio actual de la acción	€180.00
Máximo en las últimas 52 semanas	€186.70
Mínimo de 52 semanas	€67.08
Beta	0.32
1Cambio en 1 mes	0.70%
Variación en 3 meses	11.21%
Cambio de 1 año	158.55%
3Variación en 3 años	82.26%
Variación en 5 años	144.70%
Variación desde la OPV	58,890.09%

Noticias y actualizaciones recientes

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Recent updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Rentabilidad de los accionistas

	UCB	BE Pharmaceuticals	Mercado BE
7D	7.6%	3.0%	0.7%
1Y	158.5%	5.7%	3.0%

Rentabilidad vs. Industria: UCB superó a la industria Belgian Pharmaceuticals, que obtuvo un rendimiento del 5.7% el año pasado.

Rentabilidad vs. Mercado: UCB superó al mercado Belgian, que obtuvo un rendimiento del 3% el año pasado.

Volatilidad de los precios

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.8%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	3.4%
10% most volatile stocks in BE Market	6.4%
10% least volatile stocks in BE Market	2.3%

Precio estable de las acciones: UCB no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de UCB (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1925	9,000	Jean-Christophe Tellier	www.ucb.com

UCB SA, empresa biofarmacéutica, desarrolla productos y soluciones para personas con enfermedades neurológicas e inmunológicas en todo el mundo. Los principales productos de la empresa incluyen Cimzia para enfermedades inflamatorias mediadas por TNF, así como espondilitis anquilosante, espondiloartritis axial, enfermedad de Crohn, espondiloartritis axial no radiográfica, psoriasis en placas, artritis psoriásica y artritis reumatoide; Vimpat, Keppra y Briviact para la epilepsia; Neupro para la enfermedad de Parkinson y el síndrome de las piernas inquietas; Nayzilam, un tratamiento de rescate en aerosol nasal para las crisis de epilepsia; y Zyrtec y Xyzal para las alergias. También ofrece Evenity para el tratamiento de la osteoporosis en mujeres posmenopáusicas; Bimzelx para tratar la psoriasis en placas, la artritis psoriásica y la espondiloartritis axial; y Fintepla para tratar el síndrome de Dravet.

Resumen de fundamentos de UCB SA

¿Cómo se comparan los beneficios e ingresos de UCB con su capitalización de mercado?
Estadísticas fundamentales de UCB
Capitalización bursátil	€34.15b
Beneficios(TTM)	€240.00m
Ingresos (TTM)	€5.45b

142.3x

Ratio precio-beneficio (PE)

6.3x

Ratio precio-ventas (PS)

¿Está UCB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de UCB
Ingresos	€5.45b
Coste de los ingresos	€1.76b
Beneficio bruto	€3.70b
Otros gastos	€3.46b
Beneficios	€240.00m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

Feb 27, 2025

Beneficios por acción (BPA)	1.27
Margen bruto	67.80%
Margen de beneficio neto	4.40%
Ratio deuda/patrimonio	31.8%

¿Cómo se ha desempeñado UCB a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

0.8%

Rentabilidad actual por dividendo

108%

Ratio de pagos

Resumen de acción UCB

Recompensas

Análisis de riesgos

Competidores de UCB SA

ENXTBR:TUB

€6.1b

SHSE:600276

CN¥306.9b

TSE:4502

JP¥6.5t

TSE:4578

JP¥4.8t

Historial de precios y rendimiento

Noticias y actualizaciones recientes

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study